PTGX vs RARE · rev $269.8M vs rev $350.0M
Protagonist Therapeutics Inc (PTGX) versus Ultragenyx (RARE) — a side-by-side from cached financials, not a winner call.
Protagonist Therapeutics Inc (PTGX) is a biotechnology company listed on NASDAQ.
Ultragenyx (RARE) is a biotechnology company listed on US.
Latest reported PTGX revenue for 2026-06-30 was $269.8M. Net income was $166.6M. PTGX currently screens at market cap $7.25B.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
PTGX currently screens at market cap $7.25B. RARE currently screens at market cap $2.79B.
Not investment advice. Open the PTGX and RARE stock pages for the full models.
Not investment advice.